Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

Anti-OX40 medications have been associated with positive efficacy and safety outcomes for the treatment of atopic dermatitis.

Another important candidate, rocatinlimab, is being evaluated in phase III studies for atopic dermatitis and prurigo nodularis. Several data readouts are expected over the next six to 12 months, which ...

Amgen’s AMGN stock has declined 10.4% in the past three months. A lot of this price decline is related to the broader macroeconomic uncertainty. Stocks have been on a roller-coaster ride since ...

(MENAFN- GlobeNewsWire - Nasdaq) The moderate to severe atopic dermatitis market is experiencing strong growth driven by rising global prevalence and heightened awareness, fueling demand for ...

The prevalence of sleep disorders among patients with atopic dermatitis varied by subgroup, including by region, data source, study publication year, disease severity, assessment scale used, sleep ...